Xeris Biopharma Holdings, Inc. (XERS) Financials

XERS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 340.8 million 347.6 million
2023-09-30 327.8 million 323.9 million
2023-06-30 328.8 million 315.1 million
2023-03-31 321.4 million 291.3 million

XERS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 6.2 million 2.8 million
2023-09-30 -15.0 million 2.5 million
2023-06-30 -15.3 million 2.9 million
2023-03-31 -26.4 million 2.6 million

XERS Net Income

No data available :(

XERS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 72.5 million - 38.3 million
2023-09-30 66.0 million - 37.5 million
2023-06-30 80.7 million - 36.8 million
2023-03-31 95.1 million - 10.8 million

XERS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 138.1 million
2023-09-30 138.1 million
2023-06-30 137.3 million
2023-03-31 137.1 million

XERS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 132000 6.4 million 37.6 million -
2023-09-30 345000 5.0 million 37.3 million -
2023-06-30 1.5 million 6.1 million 37.6 million -
2023-03-31 238000 4.8 million 33.6 million -

XERS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 44.4 million 10.3 million
2023-09-30 48.3 million 8.2 million
2023-06-30 38.0 million 7.6 million
2023-03-31 33.2 million 5.3 million

XERS

Price: $1.89

52 week price:
1.46
3.26

Earnings Per Share: -0.45 USD

P/E Ratio: -6.24

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 485000

Market Capitalization: 266.2 million

Links: